Discover

CRSP
CRISPR Therapeutics AG
53.41
2 x 53.42
2 x 53.50
bid
ask
-
0.10
0.19%
01:40 PM
timesize
Ytd1.85%
1y-3.61%
53.22
day range
54.66
44.12
52 week range
78.48
Open54.53Prev Close53.51Low53.22High54.66Mkt Cap5.16B
Vol465.07KAvg Vol1.67MEPS-4.76P/E-11.24Forward P/E-15.26
Beta1.74Short Ratio11.26Inst. Own80.63%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1150-d Avg52.28200-d Avg53.491yr Est87.56
Income Statement
Total Revenue10.18M
Revenues (USD)10.18M
Gross Profit10.18M
Operating Expenses127.45M
Research and Development Expense107.42M
Selling, General and Administrative Expense17.55M
Operating Income-117.27M
Income Tax Expense960.00K
Net Income-91.15M
Net Income Common Stock-91.15M
Net Income Common Stock (USD)-91.15M
Consolidated Income-91.15M
Earnings per Basic Share-0.94
Earnings per Basic Share (USD)-0.94
Earnings per Diluted Share-0.94
Earning Before Interest & Taxes (EBIT)-90.19M
Earning Before Interest & Taxes (USD)-90.19M
Weighted Average Shares96.51M
Weighted Average Shares Diluted96.51M
Balance Sheet
Cash and Equivalents298.97M
Cash and Equivalents (USD)298.97M
Investments2.07B
Investments Current2.07B
Current Assets2.37B
Property, Plant & Equipment Net233.66M
Total Assets2.65B
Debt Current18.65M
Total Debt783.75M
Current Liabilities132.90M
Debt Non-Current765.10M
Total Liabilities904.22M
Accumulated Retained Earnings (Deficit)-2.16B
Accumulated Other Comprehensive Income-4.63M
Shareholders Equity1.75B
Shareholders Equity (USD)1.75B
Assets Non-Current279.00M
Total Debt (USD)783.75M
Deferred Revenue15.19M
Liabilities Non-Current771.32M
Trade and Non-Trade Payables11.31M
Tax Liabilities494.00K
Cash Flow
Depreciation, Amortization & Accretion4.28M
Net Cash Flow from Financing7.18M
Net Cash Flow / Change in Cash & Cash Equivalents-131.97M
Capital Expenditure-648.00K
Net Cash Flow - Business Acquisitions and Disposals-2.47M
Issuance (Purchase) of Equity Shares8.30M
Issuance (Repayment) of Debt Securities -1.12M
Net Cash Flow from Investing-55.66M
Net Cash Flow - Investment Acquisitions and Disposals-52.54M
Net Cash Flow from Operations-83.50M
Effect of Exchange Rate Changes on Cash 6.00K
Share Based Compensation17.32M